Christine Franzese
Adult Health · Tega Cay, SCNPI 1528302916
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $26,984 of the $30,285 with a category attached, or 89.1%. Insulet Corporation accounts for 81.4% of it on its own, with 27 other manufacturers making up the rest. Among adult health clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 180 payments — averaging $168.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insulet Corporation$25K
- Tandem Diabetes Care, Inc.$3K
- Sanofi-aventis U.S. LLC$326
- Dexcom, Inc.$314
- Novo Nordisk$280
- Bayer$249
- plus $2K from 22 others
What the payments were for
- Speaking & faculty fees$26,98489%
- Food & beverage$3,30111%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insulet Corporation | 54 | $24,663 |
| Tandem Diabetes Care, Inc. | 6 | $2,520 |
| Sanofi-aventis U.S. LLC | 15 | $326 |
| Dexcom, Inc. | 19 | $314 |
| Novo Nordisk | 10 | $280 |
| Bayer | 10 | $249 |
| Amgen(2 entities) | 8 | $236 |
| Lilly USA, LLC | 12 | $219 |
| Mannkind Corporation | 6 | $213 |
| Cequr Corporation | 4 | $195 |
| Boehringer Ingelheim | 4 | $149 |
| BETA Bionics, Inc. | 2 | $145 |
| GSK | 2 | $125 |
| Amryt Pharma Holdings Ltd | 2 | $115 |
| Medtronic | 4 | $92 |
| Recordati_rare_diseases_inc. | 4 | $85 |
| IBSA Pharma Inc. | 3 | $64 |
| Merck | 2 | $55 |
| Amneal Pharmaceuticals LLC | 2 | $43 |
| Ascensia Diabetes Care US Inc. | 1 | $37 |
| AstraZeneca | 2 | $32 |
| Tolmar, Inc. | 2 | $31 |
| Renalytix AI, Inc. | 1 | $24 |
| Madrigal Pharmaceuticals | 1 | $18 |
| Almatica Pharma LLC | 1 | $17 |
| Lifescan, Inc. | 1 | $15 |
| Nevro Corp. | 1 | $13 |
| Xeris Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnipod$24,400
- t:slim X2 Insulin Pump with Control-IQ$2,504
- iLet Bionic Pancreas$377
- AFREZZA$125
- Ozempic$125
- TEPEZZA$106
- MYCAPSSA$101
- JARDIANCE$100
How this compares
$30,285 in reported general payments places this provider in the 95th percentile of 292 adult health providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 211 | $227,678 |
| JardianceEmpagliflozin | 133 | $120,726 |
| OzempicSemaglutide | 87 | $112,371 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 49 | $66,127 |
| TrulicityDulaglutide | 42 | $60,802 |
| FarxigaDapagliflozin Propanediol | 47 | $55,240 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 19 | $44,168 |
| JanuviaSitagliptin Phosphate | 20 | $24,141 |
| Tresiba Flextouch U-100Insulin Degludec | 30 | $22,437 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 30 | $21,727 |
| Novolog FlexpenInsulin Aspart | 81 | $18,457 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 26 | $17,365 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $16,735 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $16,612 |
| Humalog Kwikpen U-100Insulin Lispro | 63 | $15,691 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Insulin Lispro | $219 | $289,127269 claims |
| Boehringer IngelheimJardiance, Tradjenta | $149 | $135,584165 claims |
| Novo NordiskOzempic, Rybelsus | $280 | $122,60098 claims |
| AstraZenecaFarxiga | $32 | $55,24047 claims |
| MerckJanuvia | $55 | $24,14120 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $43 | $95468 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 292 adult health providers in South Carolina.
Other adult health in Tega Cay
- Karen RobertsonGreenville$69K
- Jessica RiceGreenville$15K
- Michelle PriceCharleston$13K
- Melissa McCarterSpartanburg$12K
- Andrea OlsonWest Columbia$12K
- Jennifer BrittIrmo$11K
- Nichole SnowSpartanburg$10K
- Christi WigginsWest Columbia$10K
- Mary BairdSumter$10K
- Lauren DelbridgeCharleston$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.